Posts by David T. Miyamoto, MD, PhD
-
High MRE11 in Muscle-invasive Bladder Tumors Linked to Better Survival After Chemoradiation
Using a digital immunofluorescence assay, Jason A. Efstathiou, MD, DPhil, and colleagues showed the DNA repair protein MRE11 could guide the selection of candidates for bladder-sparing trimodality therapy for muscle-invasive bladder cancer, as higher levels were associated with 58% better cumulative four-year survival.
-
Gene Profiling of Bladder Tumors Shows Promise for Identifying Candidates for Trimodality Therapy
Research by Massachusetts General Hospital Cancer Center oncologists suggests gene profiling of tumors from patients with muscle-invasive bladder cancer can guide rational selection of those who will benefit most from bladder-preserving trimodality therapy.
-
Review: Molecular Biomarkers May Lead to Personalized Treatment of Muscle-invasive Bladder Cancer
Rapidly emerging molecular biomarkers will allow oncologists to choose more confidently between radical cystectomy and trimodality therapy for patients with muscle-invasive bladder cancer, as well as identify which patients undergoing trimodality therapy are likely to benefit from adding immunotherapy.
Biography
David Miyamoto, MD, PhD is an Assistant Professor of Radiation Oncology at Harvard Medical School, an attending radiation oncologist at the Massachusetts General Hospital and a physician scientist in the Center for Cancer Research in the Mass General Cancer Center. Dr. Miyamoto received his undergraduate degree in Chemistry from Harvard College, MD from Harvard Medical School, and PhD in Cell Biology from Harvard University. He completed an internship in Internal Medicine at the Brigham & Women's Hospital, and his residency in radiation oncology in the Harvard Radiation Oncology Program. Dr. Miyamoto is a board-certified radiation oncologist specializing in genitourinary malignancies who sees patients in the Bertucci Center for Genitourinary Cancers at the Mass General Cancer Center and the Mass General Department of Radiation Oncology. His research efforts focus on the development of novel biomarkers to guide prostate cancer and bladder cancer therapy, and the development of sensitive microfluidic platforms for the molecular analysis of circulating tumor cells (CTCs). He has authored and co-authored more than 35 publications in peer-reviewed scientific journals including Science, Cell, and Cancer Discovery. His research has been supported by the Prostate Cancer Foundation, Department of Defense, National Cancer Institute, and the Dana Farber/Harvard Cancer Center.
Urology Care at Mass General
The Department of Urology at Massachusetts General Hospital offers sophisticated, compassionate care and the most innovative treatments for patients with any type of urological condition.